It is worth noting that even within ACPA-negative RA patients and early RA patients, the discriminating ability of this model remained consistent with that in total RA patients, which suggested that these gene signatures may not be involved in ACPA antibody production and disease stage but in B-cell activation. This evidence concerns the gene PRTN3 and rheumatoid arthritis.